女性生殖系统肝外类癌：三例报告并文献复习
Extra-Hepatic Hepatoid Carcinomas in Female Reproductive System: Three Case-Reports with a Literature Review.
作者信息
Liu Yao, Zhou Ruiqi, Wang Shourong, Zhang Guiyu
机构信息
Department of Gynecology, Qilu Hospital of Shandong University, Jinan, Shandong Province, People's Republic of China.
Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong Province, People's Republic of China.
出版信息
Cancer Manag Res. 2021 Feb 17;13:1625-1636. doi: 10.2147/CMAR.S288913. eCollection 2021.
PURPOSE
Hepatoid carcinoma of the ovary (HCO) and hepatoid carcinoma of the uterus (HCU) are rare malignancies that can be difficult to distinguish from other diseases such as hepatocellular carcinoma. In extremely rare cases, patients are negative for α-fetoprotein (AFP) by immunohistochemistry. Here we report 3 cases of HC of the female reproductive system, including 1 that was negative for AFP.
PATIENTS AND METHODS
Three women aged 48, 56, and 67 years were treated at Qilu Hospital of Shandong University for HCO or HCU. We describe these cases in detail, including clinical features, diagnosis, treatment, and outcome, and review similar cases reported in the literature.
RESULTS
All of our patients underwent surgery including hysterectomy and bilateral adnexectomy, and were treated with platinum-based chemotherapy. One patient died 3 months after the operation, and the other 2 are alive 22 and 63 months post surgery.
CONCLUSION
The first-choice treatment for HCO and HCU is staging surgery, which should be followed by platinum-based chemotherapy.
目的
卵巢肝样癌（HCO）和子宫肝样癌（HCU）是罕见的恶性肿瘤，可能难以与其他疾病如肝细胞癌区分开来。在极为罕见的情况下，患者免疫组化检测甲胎蛋白（AFP）呈阴性。在此，我们报告3例女性生殖系统肝样癌病例，其中1例AFP呈阴性。
患者与方法
3名年龄分别为48岁、56岁和67岁的女性在山东大学齐鲁医院接受了HCO或HCU治疗。我们详细描述了这些病例，包括临床特征、诊断、治疗和结果，并回顾了文献中报道的类似病例。
结果
我们所有的患者都接受了包括子宫切除术和双侧附件切除术在内的手术，并接受了铂类化疗。1例患者术后3个月死亡，另外2例患者术后分别存活22个月和63个月。
结论
HCO和HCU的首选治疗方法是分期手术，术后应进行铂类化疗。
Zotero 插件